A Phase I Study of BR108 in Hematological Malignancies
A Phase I study of BR108 in hematological malignancies
Hematologic Malignancy
DRUG: BR108 injection
Number of Participants with Dose Limiting Toxicity (DLT), Dose limiting toxicity, up to 28 days|objective response rate（ORR）, FOR lymphoma ，Objective Response Rate is defined as the percentage of patients with a complete response (CR) or partial response (PR). For AML, the proportion of participants who achieve a best response of CR, CRi, MLFS, or partial response (PR). For MDS, the proportion of participants who achieve a best response of CR, marrow CR, or PR., up to approximately 3 years
Cmax, Cmax is the maximum observed concentration., up to approximately 3 years|Tmax, Time to maximum concentration attained, up to approximately 3 years|Incidence of antidrug antibodies (ADA), Percentage of patients producing detectable ADA, up to approximately 3 years|Duration of remission (DOR), To preliminarily evaluate DoR in patients with hematological malignancies, up to approximately 3 years
A Phase I study of BR108 in hematological malignancies